GPR30: a novel indicator of poor survival for endometrial carcinoma

Harriet O. Smith; Kimberly K. Leslie; Meenakshi Singh; Clifford R. Qualls; Chetana M. Revankar; Nancy E. Joste; Eric R. Prossnitz

doi:10.1016/j.ajog.2007.01.004

GPR30: a novel indicator of poor survival for endometrial carcinoma

Harriet O. Smith, Kimberly K. Leslie, Meenakshi Singh, Clifford R. Qualls, Chetana M. Revankar, Nancy E. Joste, Eric R. Prossnitz

Research output: Contribution to journal › Article › peer-review

201 Scopus citations

Abstract

Objective: This study was undertaken to evaluate the relationship between GPR30, classical steroidal receptor expression, and clinical outcome in patients with endometrial carcinoma. Study Design: Immunohistochemistry was used to investigate the expression of GPR30, estrogen, progesterone, epidermal growth factor receptors and Ki-67 in 47 consecutive consenting patients with endometrial carcinoma diagnosed between 1997 and 2001. Results were correlated with clinical and pathologic predictors of adverse outcome and survival. Results: GPR30 correlated positively with epidermal growth factor receptor (P = .005), but negatively with progesterone (P = .05) receptor expression. GPR30 overexpression occurred more frequently in tumors with deep myometrial invasion, high-grade, biologically aggressive histologic subtypes, and advanced stage. In patients with GPR30 overexpression, survival was significantly poorer (65.2% vs 100%, P = .005). Conclusion: GPR30 represents an alternative estrogen-responsive receptor that is overexpressed in tumors where estrogen and progesterone receptors are downregulated, and in high-risk endometrial cancer patients with lower survival rates.

Original language	English (US)
Pages (from-to)	386.e1-386.e11
Journal	American journal of obstetrics and gynecology
Volume	196
Issue number	4
DOIs	https://doi.org/10.1016/j.ajog.2007.01.004
State	Published - Apr 2007
Externally published	Yes

Keywords

GPR30
endometrial carcinoma
estrogen receptor
progesterone receptor
survival

ASJC Scopus subject areas

Obstetrics and Gynecology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ajog.2007.01.004

Cite this

@article{ce1cfaf5126247dfbde7ce7db941352c,

title = "GPR30: a novel indicator of poor survival for endometrial carcinoma",

abstract = "Objective: This study was undertaken to evaluate the relationship between GPR30, classical steroidal receptor expression, and clinical outcome in patients with endometrial carcinoma. Study Design: Immunohistochemistry was used to investigate the expression of GPR30, estrogen, progesterone, epidermal growth factor receptors and Ki-67 in 47 consecutive consenting patients with endometrial carcinoma diagnosed between 1997 and 2001. Results were correlated with clinical and pathologic predictors of adverse outcome and survival. Results: GPR30 correlated positively with epidermal growth factor receptor (P = .005), but negatively with progesterone (P = .05) receptor expression. GPR30 overexpression occurred more frequently in tumors with deep myometrial invasion, high-grade, biologically aggressive histologic subtypes, and advanced stage. In patients with GPR30 overexpression, survival was significantly poorer (65.2% vs 100%, P = .005). Conclusion: GPR30 represents an alternative estrogen-responsive receptor that is overexpressed in tumors where estrogen and progesterone receptors are downregulated, and in high-risk endometrial cancer patients with lower survival rates.",

keywords = "GPR30, endometrial carcinoma, estrogen receptor, progesterone receptor, survival",

author = "Smith, {Harriet O.} and Leslie, {Kimberly K.} and Meenakshi Singh and Qualls, {Clifford R.} and Revankar, {Chetana M.} and Joste, {Nancy E.} and Prossnitz, {Eric R.}",

note = "Funding Information: This study was supported by Pilot Research Funds (H.O.S.) from the University of New Mexico Cancer Research and Treatment Center; National Cancer Institute Grant NCI P30 CA118110; the University of New Mexico School of Medicine Grant C-2279-RAC (H.O.S.); National Institutes of Health Grants CA11666 (E.R.P.), R01CA99908-1 (K.K.L.), CA27469 (Gynecologic Oncology Group and K.K.L.), and DHHS/NIH/NCRR/GCRC Grant 5M01 RR00997; the Cory Beach Foundation; private donations (Shirley Leslie; Dean and Alice Irvin); and the Biostatistics Shared Resource of the Cancer Research and Treatment Center, University of New Mexico Health Sciences Center. Images in this article were generated in the UNM Cancer Center Fluorescence Microscopy Facility, which received support from NCRR 1 S10 RR14668, NSF MCB9982161, NCRR P20 RR11830, NCI R24 CA88339, NCRR S10 RR19287, NCRR S10 RR016918, the University of New Mexico Health Sciences Center, and the University of New Mexico Cancer Center. ",

year = "2007",

month = apr,

doi = "10.1016/j.ajog.2007.01.004",

language = "English (US)",

volume = "196",

pages = "386.e1--386.e11",

journal = "American journal of obstetrics and gynecology",

issn = "0002-9378",

publisher = "Mosby Inc.",

number = "4",

}

TY - JOUR

T1 - GPR30

T2 - a novel indicator of poor survival for endometrial carcinoma

AU - Smith, Harriet O.

AU - Leslie, Kimberly K.

AU - Singh, Meenakshi

AU - Qualls, Clifford R.

AU - Revankar, Chetana M.

AU - Joste, Nancy E.

AU - Prossnitz, Eric R.

N1 - Funding Information: This study was supported by Pilot Research Funds (H.O.S.) from the University of New Mexico Cancer Research and Treatment Center; National Cancer Institute Grant NCI P30 CA118110; the University of New Mexico School of Medicine Grant C-2279-RAC (H.O.S.); National Institutes of Health Grants CA11666 (E.R.P.), R01CA99908-1 (K.K.L.), CA27469 (Gynecologic Oncology Group and K.K.L.), and DHHS/NIH/NCRR/GCRC Grant 5M01 RR00997; the Cory Beach Foundation; private donations (Shirley Leslie; Dean and Alice Irvin); and the Biostatistics Shared Resource of the Cancer Research and Treatment Center, University of New Mexico Health Sciences Center. Images in this article were generated in the UNM Cancer Center Fluorescence Microscopy Facility, which received support from NCRR 1 S10 RR14668, NSF MCB9982161, NCRR P20 RR11830, NCI R24 CA88339, NCRR S10 RR19287, NCRR S10 RR016918, the University of New Mexico Health Sciences Center, and the University of New Mexico Cancer Center.

PY - 2007/4

Y1 - 2007/4

N2 - Objective: This study was undertaken to evaluate the relationship between GPR30, classical steroidal receptor expression, and clinical outcome in patients with endometrial carcinoma. Study Design: Immunohistochemistry was used to investigate the expression of GPR30, estrogen, progesterone, epidermal growth factor receptors and Ki-67 in 47 consecutive consenting patients with endometrial carcinoma diagnosed between 1997 and 2001. Results were correlated with clinical and pathologic predictors of adverse outcome and survival. Results: GPR30 correlated positively with epidermal growth factor receptor (P = .005), but negatively with progesterone (P = .05) receptor expression. GPR30 overexpression occurred more frequently in tumors with deep myometrial invasion, high-grade, biologically aggressive histologic subtypes, and advanced stage. In patients with GPR30 overexpression, survival was significantly poorer (65.2% vs 100%, P = .005). Conclusion: GPR30 represents an alternative estrogen-responsive receptor that is overexpressed in tumors where estrogen and progesterone receptors are downregulated, and in high-risk endometrial cancer patients with lower survival rates.

AB - Objective: This study was undertaken to evaluate the relationship between GPR30, classical steroidal receptor expression, and clinical outcome in patients with endometrial carcinoma. Study Design: Immunohistochemistry was used to investigate the expression of GPR30, estrogen, progesterone, epidermal growth factor receptors and Ki-67 in 47 consecutive consenting patients with endometrial carcinoma diagnosed between 1997 and 2001. Results were correlated with clinical and pathologic predictors of adverse outcome and survival. Results: GPR30 correlated positively with epidermal growth factor receptor (P = .005), but negatively with progesterone (P = .05) receptor expression. GPR30 overexpression occurred more frequently in tumors with deep myometrial invasion, high-grade, biologically aggressive histologic subtypes, and advanced stage. In patients with GPR30 overexpression, survival was significantly poorer (65.2% vs 100%, P = .005). Conclusion: GPR30 represents an alternative estrogen-responsive receptor that is overexpressed in tumors where estrogen and progesterone receptors are downregulated, and in high-risk endometrial cancer patients with lower survival rates.

KW - GPR30

KW - endometrial carcinoma

KW - estrogen receptor

KW - progesterone receptor

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=33947697810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947697810&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2007.01.004

DO - 10.1016/j.ajog.2007.01.004

M3 - Article

C2 - 17403429

AN - SCOPUS:33947697810

SN - 0002-9378

VL - 196

SP - 386.e1-386.e11

JO - American journal of obstetrics and gynecology

JF - American journal of obstetrics and gynecology

IS - 4

ER -

GPR30: a novel indicator of poor survival for endometrial carcinoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this